Siemens Makes First Molecular Dx Buy In Nine Years
This article was originally published in The Gray Sheet
Executive Summary
The firm's health-care division bought private next-generation sequencing firm NEO New Oncology for an undisclosed amount.
You may also be interested in...
Siemens Claims Top IVD Slot With $7 Billion Dade Behring Purchase
Siemens' medical unit solidified its status July 25 as the only company offering a comprehensive suite of both imaging and in vitro diagnostic products with its $7 billion acquisition of Dade Behring
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.
SyncThink Brings Eye-Sync Neurological Diagnostic To Europe
SyncThink recently obtained a CE mark for the Eye-Sync system, using the PicoXR Neo 3 Pro Eye virtual-reality headset, to measure and quantify eye-movement biomarkers reflective of neurological impairment or disease.